CARMELINA: Linagliptin lowers albuminuria in T2D patients with nephrotic-range proteinuria
26 Jan 2021
byJairia Dela Cruz
In patients with type 2 diabetes (T2D) and nephrotic-range proteinuria, treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin helps reduce albuminuria burden and manage blood sugar at the same time, without increasing the risk of adverse cardiovascular or kidney events, according to data from the CARMELINA trial.